DK3258938T3 - Phenothiazinanaloger som mitokondrie terapeutiske midler - Google Patents

Phenothiazinanaloger som mitokondrie terapeutiske midler Download PDF

Info

Publication number
DK3258938T3
DK3258938T3 DK16752964.3T DK16752964T DK3258938T3 DK 3258938 T3 DK3258938 T3 DK 3258938T3 DK 16752964 T DK16752964 T DK 16752964T DK 3258938 T3 DK3258938 T3 DK 3258938T3
Authority
DK
Denmark
Prior art keywords
mitocondries
analoges
phenothiazine
therapeutic medicines
medicines
Prior art date
Application number
DK16752964.3T
Other languages
Danish (da)
English (en)
Inventor
Sidney Hecht
Omar Khdour
Indrajit Bandyopadhay
Sandipan Roy Chowdhury
Original Assignee
Univ Arizona State
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Arizona State filed Critical Univ Arizona State
Application granted granted Critical
Publication of DK3258938T3 publication Critical patent/DK3258938T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D279/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/101,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/141,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
    • C07D279/18[b, e]-condensed with two six-membered rings
    • C07D279/20[b, e]-condensed with two six-membered rings with hydrogen atoms directly attached to the ring nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D279/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/101,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/141,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
    • C07D279/18[b, e]-condensed with two six-membered rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK16752964.3T 2015-02-17 2016-02-17 Phenothiazinanaloger som mitokondrie terapeutiske midler DK3258938T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562117205P 2015-02-17 2015-02-17
PCT/US2016/018233 WO2016133995A1 (en) 2015-02-17 2016-02-17 Phenothiazine analogues as mitochondrial therapeutic agents

Publications (1)

Publication Number Publication Date
DK3258938T3 true DK3258938T3 (da) 2021-02-01

Family

ID=56692740

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16752964.3T DK3258938T3 (da) 2015-02-17 2016-02-17 Phenothiazinanaloger som mitokondrie terapeutiske midler

Country Status (7)

Country Link
US (3) US10472340B2 (https=)
EP (1) EP3258938B1 (https=)
JP (3) JP6807337B2 (https=)
AU (3) AU2016220096B2 (https=)
CA (1) CA2976776C (https=)
DK (1) DK3258938T3 (https=)
WO (1) WO2016133995A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016133995A1 (en) 2015-02-17 2016-08-25 Arizona Board Of Regents On Behalf Of Arizona State University Phenothiazine analogues as mitochondrial therapeutic agents
US10364227B2 (en) 2015-02-17 2019-07-30 Arizona Board Of Regents On Behalf Of Arizona State University Therapeutic compounds
US10604501B2 (en) 2016-06-15 2020-03-31 Arizona Board Of Regents On Behalf Of Arizona State University Prodrug and profluorescent compounds for selective mitochondrial imaging and therapeutic targeting
US11390605B2 (en) 2016-08-25 2022-07-19 Arizona Board Of Regents On Behalf Of Arizona State University Substituted pyrimidine compounds as multifunctional radical quenchers and their uses
WO2018039487A1 (en) 2016-08-25 2018-03-01 Arizona Board Of Regents On Behalf Of Arizona State University Therapeutic compounds
US12570622B2 (en) 2016-08-25 2026-03-10 Arizona Board Of Regents On Behalf Of Arizona State University Therapeutic compounds
WO2018129411A1 (en) * 2017-01-06 2018-07-12 Bioelectron Technology Corporation Aryl- and heteroaryl-resorufin derivatives for treatment of oxidative stress disorders and liver and kidney disorders
FR3063495B1 (fr) * 2017-03-02 2019-04-05 Provepharm Life Solutions Procede de preparation de l’iodure de 3,7-bis(dimethylamino)phenothiazine-5-ylium
CN108484527B (zh) * 2018-04-27 2022-01-14 成都恒昊创新科技有限公司 一种10h-吩噻嗪类铁死亡抑制剂及其制备方法与应用
WO2020021536A1 (en) 2018-07-22 2020-01-30 Minovia Therapeutics Ltd. Mitochondrial augmentation therapy for primary mitochondrial diseases
DK3826639T3 (da) * 2018-07-26 2024-09-23 Wista Lab Ltd Optimeret dosering af diaminophenothiaziner i populationer
US12110313B2 (en) 2019-02-28 2024-10-08 Arizona Board Of Regents On Behalf Of Arizona State University Engineered bacterial ribosome compositions and methods
WO2022171265A1 (en) * 2021-02-09 2022-08-18 Boehringer Ingelheim International Gmbh Modulators of complex i
CN119504646A (zh) * 2024-11-07 2025-02-25 长春工业大学 新型含有吩噻嗪结构药物小分子的合成及抗肿瘤活性研究

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3476722A (en) 1966-08-15 1969-11-04 Goodrich Co B F Process for polymerizing acrylic acid esters
DE2315349A1 (de) 1973-03-28 1974-10-03 Bayer Ag Nicht verfaerbende alterungsschutzmittel
JPS5168569A (en) 1974-12-10 1976-06-14 Fuji Photo Film Co Ltd 2 2 44 torimechiru 66 hidorokishi 77 chikankuromanruino seizoho
FR2471052B1 (fr) 1979-11-28 1985-10-11 Kuraray Co Photo-electrode pour cellule photo-electrochimique et son procede de fabrication
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US5220042A (en) 1984-01-26 1993-06-15 Otsuka Pharmaceutical Co., Ltd. 1,4-benzoquinone derivatives and benzene derivatives, and process for preparing the same
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
CA2099868C (en) 1991-01-31 2002-04-02 Thomas Richard Belliotti Substituted 4,6-di-tertiary-butyl-5-hydroxy-pyrimidines
WO1996031217A1 (en) 1995-04-04 1996-10-10 Duke University Inhibiting retroviral replication
JP2001209176A (ja) 1999-04-02 2001-08-03 Fuji Photo Film Co Ltd 光重合性組成物およびそれを用いた記録材料
JP4064671B2 (ja) 2000-02-25 2008-03-19 エフ.ホフマン−ラ ロシュ アーゲー アデノシン受容体モジュレーター
WO2002000683A2 (en) 2000-06-23 2002-01-03 Vanderbilt University Novel chain-breaking antioxidants
AU2002319583B2 (en) 2001-07-20 2005-08-25 Eli Lilly And Company (Pyridinyl and pyrimidyl) trienoic acid derivatives as retinoid X receptor modulators
MXPA04012559A (es) 2002-06-17 2005-09-21 Verification Technologies Inc Materiales para proteccion contra copias de medio optico que reacciona transitoriamente a un haz de lector.
CA2505603A1 (en) 2002-11-18 2004-06-03 Genospectra, Inc. Caged sensors, regulators and compounds and uses thereof
US20060188866A1 (en) 2005-02-18 2006-08-24 Children's Hospital Oakland Research Institute Diaminophenothiazine compositions and uses thereof
EP1863796A1 (en) 2005-03-22 2007-12-12 NeuroSearch A/S Pyrazolyl-pyrimidines as potassium channel modulating agents and their medical use
DK3121169T3 (da) 2006-07-11 2022-02-28 Wista Lab Ltd Fremgangsmåder til syntese og/eller oprensning af diaminophenothiaziniumforbindelser
CN101820884B (zh) * 2007-06-19 2013-08-28 维斯塔实验室有限公司 用于治疗轻度认知缺损的吩噻嗪化合物
US8268849B2 (en) 2007-09-25 2012-09-18 Board Of Regents Of The University Of Nebraska Multifunctional Antioxidants and methods of use thereof
EP2268311A4 (en) 2008-04-04 2014-08-27 Immunolight Llc NON-INVASIVE SYSTEMS AND IN SITU PHOTOBIOMODULATION METHODS
US8389583B2 (en) 2008-05-23 2013-03-05 Zurex Pharma, Inc. Antimicrobial compositions and methods of use
CA2784830C (en) 2009-12-18 2018-03-27 Sunovion Pharmaceuticals Inc. Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof
ES2687177T3 (es) 2010-02-19 2018-10-24 Arizona Board Of Regents, A body corporate of the State of Arizona acting, For and on behalf of Arizona State University Inhibidores de radicales multifuncionales y su uso
CN102958525B (zh) * 2010-04-30 2017-05-24 普罗瑟塔抗病毒股份有限公司 抗病毒化合物
WO2012022467A2 (en) 2010-08-16 2012-02-23 Santhera Pharmaceuticals (Schweiz) Ag Novel benzoquinone derivatives and use thereof as modulators of mitochondrial function
DE102010043379A1 (de) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung
EP2450893A1 (de) * 2010-11-08 2012-05-09 Bayer MaterialScience AG Photopolymer-Formulierung zur Herstellung holographischer Medien mit hoch vernetzten Matrixpolymeren
WO2012125983A1 (en) 2011-03-17 2012-09-20 Prosetta Antiviral Inc. Antiviral treatments
CA2830581A1 (en) 2011-04-04 2012-10-11 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University Multifunctional radical quenchers for the treatment of mitochondrial dysfunction
KR101270160B1 (ko) 2011-05-16 2013-05-31 아주대학교산학협력단 가변색 이광자 형광프로브, 이를 이용한 미토콘드리아 내 티올 활성의 영상화 방법 및 이의 제조방법
US9440967B2 (en) 2012-02-10 2016-09-13 Arizona Board Of Regents On Behalf Of Arizona State University 1H-pyrrolo [2, 3 -B] pyridine derivatives and their use as radical quenchers
WO2013120040A1 (en) 2012-02-10 2013-08-15 Children's Medical Center Corporation Targeted pathway inhibition to improve muscle structure, function and activity in muscular dystrophy
US9334250B2 (en) 2012-10-03 2016-05-10 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of Arizona State University Multifunctional radical quenchers for the treatment of mitochondrial dysfunction
JP2016501832A (ja) 2012-10-10 2016-01-21 アリゾナ ボード オブ リージェンツ オン ビハーフ オブ アリゾナ ステート ユニバーシティ 多機能ラジカル消光剤
US20140275045A1 (en) 2013-03-15 2014-09-18 Edison Pharmaceuticals, Inc. Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders
US10364227B2 (en) 2015-02-17 2019-07-30 Arizona Board Of Regents On Behalf Of Arizona State University Therapeutic compounds
WO2016133995A1 (en) 2015-02-17 2016-08-25 Arizona Board Of Regents On Behalf Of Arizona State University Phenothiazine analogues as mitochondrial therapeutic agents
US10604501B2 (en) 2016-06-15 2020-03-31 Arizona Board Of Regents On Behalf Of Arizona State University Prodrug and profluorescent compounds for selective mitochondrial imaging and therapeutic targeting
US11390605B2 (en) 2016-08-25 2022-07-19 Arizona Board Of Regents On Behalf Of Arizona State University Substituted pyrimidine compounds as multifunctional radical quenchers and their uses
WO2018039487A1 (en) 2016-08-25 2018-03-01 Arizona Board Of Regents On Behalf Of Arizona State University Therapeutic compounds

Also Published As

Publication number Publication date
JP7113055B2 (ja) 2022-08-04
EP3258938B1 (en) 2020-12-02
JP6807337B2 (ja) 2021-01-06
WO2016133995A1 (en) 2016-08-25
JP2018505228A (ja) 2018-02-22
US11034662B2 (en) 2021-06-15
US10472340B2 (en) 2019-11-12
US20200115355A1 (en) 2020-04-16
JP2021006573A (ja) 2021-01-21
AU2016220096B2 (en) 2020-01-30
AU2016220096A1 (en) 2017-08-31
CA2976776C (en) 2023-06-20
US20220081404A1 (en) 2022-03-17
EP3258938A4 (en) 2018-10-31
US20180065941A1 (en) 2018-03-08
CA2976776A1 (en) 2016-08-25
JP2022141896A (ja) 2022-09-29
AU2020202836B2 (en) 2020-12-17
AU2021201137A1 (en) 2021-03-11
EP3258938A1 (en) 2017-12-27
AU2020202836A1 (en) 2020-05-21

Similar Documents

Publication Publication Date Title
IL290823A (en) Pharmaceutical compositions for combination therapy
IL282304A (en) Topical pharmaceutical compositions
IL260383B (en) Low dose therapeutic treatment
DK3328880T3 (da) Terapeutiske midler
DK3258938T3 (da) Phenothiazinanaloger som mitokondrie terapeutiske midler
DK3229810T3 (da) Phospholipid-ether-analoger som kræftrammende lægemiddelvehikler
EP3344318A4 (en) Patient interfaces
EP3522966A4 (en) PATIENT INTERFACES
SI3529248T1 (sl) Farmacevtske spojine
EP3291824C0 (en) ANTIMICROBIAL THERAPY
DK3265421T3 (da) Doseringssystem
PT4070788T (pt) Formulações farmacêuticas
HUE054344T2 (hu) Gyógyászati készítmények AZD9291 tartalommal
BR112016018062A2 (pt) compostos terapêuticos, composição farmacêutica e usos
MA42303A (fr) Formulations pharmaceutiques
DK3529240T3 (da) Farmaceutiske forbindelser
DK3380146T3 (da) Medikamentadministrationsanordning
EP3424940A4 (en) Radiolabeled drug
EP3246047C0 (en) COMBINATION MEDICATION
EP3437644A4 (en) MEDICINE
DK3280447T3 (da) Farmaceutiske formuleringer
EP3334447A4 (en) CCK2R-drug conjugates
EP3337463A4 (en) PHARMACEUTICAL FORMULATIONS
DK3313370T3 (da) Oftalmologisk farmaceutisk sammensætning
EP3305294A4 (en) AQUEOUS MEDICINE